Releases Details
Director/PDMR Shareholding
Released : February 28, 2018 17:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings
Following the sale, J. Stark Thompson holds a total of 110,918 Common Stock representing a total of 0.2% of the issued share capital of the Company and a further 213,633 options over common stock.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
J. Stark Thompson |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Chairman and PDMR |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MaxCyte, Inc. |
|
|
b) |
LEI |
54930053YHXULRFCU991 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Sale of Common Stock |
|
|
b) |
Identification Code |
US57777K1060 |
|
|
c) |
Nature of the transaction |
Sale of Common Stock by PDMR |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
24,000 |
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A (Single Transaction) 24,000 246.00 |
|
|
f) |
Date of the transaction |
28 February 2018 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
|
For further information, please contact:
|
MaxCyte Inc. |
|
|
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer |
+1 301 944 1660 |
|
Nominated Adviser and Broker Panmure Gordon |
|
|
Freddy Crossley (Corporate Finance) Ryan McCarthy Tom Salvesen (Corporate Broking) |
+44 (0) 20 7886 2500
|
|
Financial PR Adviser Consilium Strategic Communications |
|
|
Mary-Jane Elliott Chris Welsh Suki Virji
|
+44 (0)203 709 5700 |
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering enabling technology to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery technology, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This technology allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering enabling technology is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumours where existing CAR-T approaches face significant challenges. For more information, visit http://www.maxcyte.com/.
This information is provided by RNS
